一项回顾性队列研究评估剂量调整EPOCH(+/−R)方案治疗hiv相关高级别b细胞非霍奇金淋巴瘤(NHL)的结果

IF 0.7 4区医学 Q4 HEMATOLOGY

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-01-01 Epub Date: 2023-04-21 DOI:10.1007/s12288-023-01652-3

Jayashree Thorat, Manju Sengar, Raajit Chanana, Akhil Kapoor, Ajay Singh, Avinash Bonda, Hari Menon, Bhausaheb Bagal, Siddharth Laskar, Nehal Khanna, Jayant Shastri Goda, Epari Sridhar, Sumeet Gujral, Archi Agarwal, Sheela Sawant, Anuprita Daddi, Tanuja Shet, Netra Ghandade, Hasmukh Jain

{"title":"一项回顾性队列研究评估剂量调整EPOCH(+/−R)方案治疗hiv相关高级别b细胞非霍奇金淋巴瘤(NHL)的结果","authors":"Jayashree Thorat, Manju Sengar, Raajit Chanana, Akhil Kapoor, Ajay Singh, Avinash Bonda, Hari Menon, Bhausaheb Bagal, Siddharth Laskar, Nehal Khanna, Jayant Shastri Goda, Epari Sridhar, Sumeet Gujral, Archi Agarwal, Sheela Sawant, Anuprita Daddi, Tanuja Shet, Netra Ghandade, Hasmukh Jain","doi":"10.1007/s12288-023-01652-3","DOIUrl":null,"url":null,"abstract":"High-grade B-cell NHL's are more common in seropositive patients. They are biologically different from their seronegative counterparts. We report our analysis on our cohort of patients who were treated with DA-EPOCH(+/-R). We retrospectively analyzed treatment-naïve HIV-associated High-grade B-cell NHL patients (aged ≥ 18) treated with DA-EPOCH(+/-R) regimen from 2011 to 2015. Descriptive statistics were summarized with median and range; survival outcomes were analyzed with Kaplan-Meier method. The cohort comprised of 40 patients [DLBCL(19), Burkitt's Lymphoma(16), High-grade B-Cell Lymphoma-Unclassifiable(09), and Plasmablastic Lymphoma(01)] and the median CD4 + T cell count was 202/mm3. CNS prophylaxis was administered with intrathecal methotrexate to 90% of patients. With a median follow-up of 72 months, an estimated 5-year OS was 82.5%, and 5-PFS was 77.5%. There were 9 deaths, and 9 patients had progression. At least 4 cycles of chemotherapy were administered to 35 (93%) patients, with 28 (70%) receiving 6 cycles. Grade 3-4 toxicities were seen in 33 (83%) patients- febrile neutropenia (65%) being the most common followed by mucositis (25%) and peripheral neuropathy (13%). There was no difference in survival based on IPI, CD 4 + T cell count, CDI, or duration of HIV. DA-EPOCH(+/-R) is a highly effective regimen in seropositive high-grade B-cell lymphoma, even in the presence of adverse features.Supplementary information: The online version contains supplementary material available at 10.1007/s12288-023-01652-3.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830987/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Retrospective Cohort Study to Evaluate the Outcomes of HIV-Associated High-Grade B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Dose Adjusted EPOCH (+/-R) Regimen.\",\"authors\":\"Jayashree Thorat, Manju Sengar, Raajit Chanana, Akhil Kapoor, Ajay Singh, Avinash Bonda, Hari Menon, Bhausaheb Bagal, Siddharth Laskar, Nehal Khanna, Jayant Shastri Goda, Epari Sridhar, Sumeet Gujral, Archi Agarwal, Sheela Sawant, Anuprita Daddi, Tanuja Shet, Netra Ghandade, Hasmukh Jain\",\"doi\":\"10.1007/s12288-023-01652-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"High-grade B-cell NHL's are more common in seropositive patients. They are biologically different from their seronegative counterparts. We report our analysis on our cohort of patients who were treated with DA-EPOCH(+/-R). We retrospectively analyzed treatment-naïve HIV-associated High-grade B-cell NHL patients (aged ≥ 18) treated with DA-EPOCH(+/-R) regimen from 2011 to 2015. Descriptive statistics were summarized with median and range; survival outcomes were analyzed with Kaplan-Meier method. The cohort comprised of 40 patients [DLBCL(19), Burkitt's Lymphoma(16), High-grade B-Cell Lymphoma-Unclassifiable(09), and Plasmablastic Lymphoma(01)] and the median CD4 + T cell count was 202/mm3. CNS prophylaxis was administered with intrathecal methotrexate to 90% of patients. With a median follow-up of 72 months, an estimated 5-year OS was 82.5%, and 5-PFS was 77.5%. There were 9 deaths, and 9 patients had progression. At least 4 cycles of chemotherapy were administered to 35 (93%) patients, with 28 (70%) receiving 6 cycles. Grade 3-4 toxicities were seen in 33 (83%) patients- febrile neutropenia (65%) being the most common followed by mucositis (25%) and peripheral neuropathy (13%). There was no difference in survival based on IPI, CD 4 + T cell count, CDI, or duration of HIV. DA-EPOCH(+/-R) is a highly effective regimen in seropositive high-grade B-cell lymphoma, even in the presence of adverse features.Supplementary information: The online version contains supplementary material available at 10.1007/s12288-023-01652-3.\",\"PeriodicalId\":49188,\"journal\":{\"name\":\"Indian Journal of Hematology and Blood Transfusion\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830987/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Hematology and Blood Transfusion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12288-023-01652-3\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/4/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-023-01652-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

高级别 B 细胞 NHL 在血清反应阳性患者中更为常见。它们在生物学上与血清阴性患者不同。我们报告了对接受 DA-EPOCH(+/-R) 治疗的患者队列的分析结果。我们回顾性分析了2011年至2015年接受DA-EPOCH(+/-R)方案治疗的HIV相关高级别B细胞NHL患者（年龄≥18岁）。描述性统计用中位数和范围进行总结；生存结果用 Kaplan-Meier 法进行分析。队列由40名患者组成[DLBCL(19)、Burkitt淋巴瘤(16)、高级别B细胞淋巴瘤-无法分类(09)和浆细胞性淋巴瘤(01)]，CD4 + T细胞计数中位数为202/mm3。90%的患者使用鞘内甲氨蝶呤进行中枢神经系统预防治疗。中位随访时间为72个月，估计5年OS为82.5%，5-PFS为77.5%。9例患者死亡，9例患者病情恶化。35名患者（93%）接受了至少4个周期的化疗，其中28名患者（70%）接受了6个周期的化疗。33名患者（83%）出现了3-4级毒性反应--最常见的是发热性中性粒细胞减少（65%），其次是粘膜炎（25%）和周围神经病变（13%）。根据 IPI、CD 4 + T 细胞计数、CDI 或感染艾滋病毒的时间长短，存活率没有差异。DA-EPOCH(+/-R)是治疗血清阳性高级别B细胞淋巴瘤的高效方案，即使存在不良特征：在线版本包含补充材料，可在10.1007/s12288-023-01652-3网站上查阅。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A Retrospective Cohort Study to Evaluate the Outcomes of HIV-Associated High-Grade B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Dose Adjusted EPOCH (+/-R) Regimen.

查看原文本刊更多论文

A Retrospective Cohort Study to Evaluate the Outcomes of HIV-Associated High-Grade B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Dose Adjusted EPOCH (+/-R) Regimen.

High-grade B-cell NHL's are more common in seropositive patients. They are biologically different from their seronegative counterparts. We report our analysis on our cohort of patients who were treated with DA-EPOCH(+/-R). We retrospectively analyzed treatment-naïve HIV-associated High-grade B-cell NHL patients (aged ≥ 18) treated with DA-EPOCH(+/-R) regimen from 2011 to 2015. Descriptive statistics were summarized with median and range; survival outcomes were analyzed with Kaplan-Meier method. The cohort comprised of 40 patients [DLBCL(19), Burkitt's Lymphoma(16), High-grade B-Cell Lymphoma-Unclassifiable(09), and Plasmablastic Lymphoma(01)] and the median CD4 + T cell count was 202/mm³. CNS prophylaxis was administered with intrathecal methotrexate to 90% of patients. With a median follow-up of 72 months, an estimated 5-year OS was 82.5%, and 5-PFS was 77.5%. There were 9 deaths, and 9 patients had progression. At least 4 cycles of chemotherapy were administered to 35 (93%) patients, with 28 (70%) receiving 6 cycles. Grade 3-4 toxicities were seen in 33 (83%) patients- febrile neutropenia (65%) being the most common followed by mucositis (25%) and peripheral neuropathy (13%). There was no difference in survival based on IPI, CD 4 + T cell count, CDI, or duration of HIV. DA-EPOCH(+/-R) is a highly effective regimen in seropositive high-grade B-cell lymphoma, even in the presence of adverse features.

Supplementary information: The online version contains supplementary material available at 10.1007/s12288-023-01652-3.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Hematology and Blood Transfusion HEMATOLOGY-

CiteScore

1.70

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.